title: Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: a brief review.
abstract: Iron overload is a frequent consequence in transfusion-dependent myelodysplastic syndromes (MDSs), which often requires iron chelation therapy (ICT). Interestingly, ICT may sometimes induce a hematologic improvement that leads to significant reduction or complete interruption of blood transfusions. This phenomenon has been recently described in MDS treated with the new oral chelator deferasirox. Here we briefly review the literature about this phenomenon and discuss the possible biological mechanisms underlying hematologic effects of deferasirox in MDS, starting from a new paradigmatic case in whom both hemoglobin level and platelet count improved, inducing transfusion-independence, soon after starting the treatment with deferasirox.
authors.affiliation: Department of Onco-Hematology, Centro di Riferimento Oncologico della Basilicata, IRCCS, Via San Pio 1, 85028 Rionero in Vulture, PZ, Italy.
authors.forename: Roberto
authors.initials: R
authors.lastname: Guariglia
authors.forename: Maria Carmen
authors.initials: MC
authors.lastname: Martorelli
authors.forename: Oreste
authors.initials: O
authors.lastname: Villani
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Pietrantuono
authors.forename: Giovanna
authors.initials: G
authors.lastname: Mansueto
authors.forename: Fiorella
authors.initials: F
authors.lastname: D'Auria
authors.forename: Vitina
authors.initials: V
authors.lastname: Grieco
authors.forename: Gabriella
authors.initials: G
authors.lastname: Bianchino
authors.forename: Rosa
authors.initials: R
authors.lastname: Lerose
authors.forename: Giovanni Battista
authors.initials: GB
authors.lastname: Bochicchio
authors.forename: Pellegrino
authors.initials: P
authors.lastname: Musto
mesh_terms: D000284:Administration, Oral; D000368:Aged; D001565:Benzoates / Q000008:administration & dosage* / Q000494:pharmacology*; D015913:Chelation Therapy / Q000379:methods; D000077588:Deferasirox; D006410:Hematopoiesis / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D007502:Iron Chelating Agents / Q000008:administration & dosage / Q000494:pharmacology; D008297:Male; D009190:Myelodysplastic Syndromes / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology / Q000628:therapy*; D065227:Transfusion Reaction; D014230:Triazoles / Q000008:administration & dosage* / Q000494:pharmacology*; D015854:Up-Regulation / Q000187:drug effects
chemical_list: D001565:Benzoates; D007502:Iron Chelating Agents; D014230:Triazoles; D000077588:Deferasirox